Search Results
559 items found for "Gorostiola González M"
- Structure Therapeutics Extends Financing, Advances Diabetes and Obesity Clinical Program and...
., today announced it closed an oversubscribed $33 million financing round, extending its $100 million Read more at the source #DrGPCR #GPCR #IndustryNews
- Amgen to Acquire Chemocentryx for $4 Billion in Cash
Read more at the source #DrGPCR #GPCR #IndustryNews
- Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in...
NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines The trial met its primary endpoint, with KarXT demonstrating a statistically significant and clinically meaningful 9.6-point reduction in the Positive and Negative Syndrome Scale (PANSS) total score compared statistically significant reduction of symptoms, as assessed by PANSS total score, starting at Week 2 and maintained Read more at the source #DrGPCR #GPCR #IndustryNews
- Addex Reports 2022 Half Year and Second Quarter Financial Results and Provides Corporate Update
Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based Read more at the source #DrGPCR #GPCR #IndustryNews
- Trevena Reports Second Quarter 2022 Results and Provides Business Update
Nasdaq:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines Read more at the source #DrGPCR #GPCR #IndustryNews
- Anatomy of a partnership: Cancer Research UK teams up with Sosei Heptares
Jonah Comstock delves into what makes this team-up tick. Cancer Research UK , a charity dedicated to funding lifesaving oncology research, spent £388 million Much of that funding is distributed to support third party research, but the group also does its own Read more at the source #DrGPCR #GPCR #IndustryNews
- Discovery of 3(2-aminoethyl)-thiazolidine-2,4-diones as a novel chemotype of sigma-1 receptor ligand
August 2022 "Abstract Sigma receptor is a transmembrane non-GPCR protein expressed mainly in the endoplasmic reticulum membrane associated with mitochondria. S1R has been implicated in many neurological disorders such as anxiety, schizophrenia, and depression Moreover, compounds 6c and 6e showed a significant selectivity over S2R. Read more at the source #DrGPCR #GPCR #IndustryNews
- X4 slashes pipeline, lays off staff just three weeks after netting a $55M PIPE
biotech revealed Wednesday afternoon that it would downsize its research to focus on its lead program, mavorixafor The move comes less than three weeks after X4 pulled together a $55 million PIPE and amended a loan facility Read more at the source #DrGPCR #GPCR #IndustryNews
- Dr. Ross Bathgate becomes Scientific co-founder of LASEREDD Therapeutics
that I’m starting a new position as Scientific co-founder LASEREDD Therapeutics " Ross Bathgate Read more
- Tectonic Therapeutic Strengthens Leadership Team
Coupled Receptors), today announced the promotion of Senior Vice President, Head of Research, Peter McNamara Rubenstein as Senior Vice President, People and Culture and Washington Alves as Vice President, Biologics Manufacturing Read more at the source #DrGPCR #GPCR #IndustryNews
- Sosei Heptares recently hosted their annual Scientific Advisory Board (SAB)
It was great to bring everyone together and also welcome new member John Parkinson ." Read more at the source #DrGPCR #GPCR #IndustryNews
- Exscientia is 10 years old this July!
the first-ever AI-designed drug candidates to enter clinical trials, the first AI-driven precision medicine #artificialintelligence #drugdesign #drugdiscovery" Read more at the source #DrGPCR #GPCR #IndustryNews
- Cancer Research UK and Sosei Heptares sign agreement to advance cancer immunotherapy candidate ...
Read more at the source #DrGPCR #GPCR #IndustryNews
- GPCR Therapeutics welcomes Dr. Ed Brennan as their new Vice President, Head of Clinical Development
Dr Brennan has extensive experience across all phases of clinical development, and across multiple therapeutic He has led teams that have filed more than 10 Investigational New Drug Applications (IND), as well as multiple New Drug (NDA) and Supplemental New Drug Applications (SNDA). He went on to study medicine at the Royal College of Surgeons in Ireland before receiving his Medical Degree from Temple University – Lewis Katz School of Medicine.
- Orion Shares New Data on its Latest Best-in-Class Drug Candidate
June 2022 "Ottawa, Canada, May 10, 2022 — Orion Biotechnology Canada Ltd, a drug discovery and development important new data at both LSX World Congress and TIDES USA 2022 conference, taking place this week – May Read more at the source #DrGPCR #GPCR #IndustryNews
- Crinetics Presents Clinical And Research Results At ENDO 2022
hormone (ACTH), were selected for an oral presentation at ENDO 2022, the Endocrine Society’s annual meeting hour urine free cortisol excretion in the presence of sustained, disease-like ACTH concentrations in multiple-ascending Read more at the source #DrGPCR #GPCR #IndustryNews
- Neurocrine Biosciences Presents Data on Treatment of Adolescent Patients with Classic Congenital ...
Newfield, M.D., University of California , San Diego and Rady Children's Hospital, San Diego on June ET (Presentation #OR18) at ENDO 2022, the Endocrine Society's 104th annual meeting in Atlanta from June Read more at the source #DrGPCR #GPCR #IndustryNews
- Accelerating GPCR Drug Discovery With Conformation-Stabilizing VHHs
June 2022 "G protein-coupled receptors (GPCRs) represent a major therapeutic target class as they play a key role in many (patho-) physiological processes. GPCRs continue to be regarded as one of the most tractable classes of drug targets and are targeted by approximately 850 GPCRs) has been successfully drugged, and obtaining highly potent and selective small molecules Read more at the source #DrGPCR #GPCR #IndustryNews
- Inversago Pharma appoints Glenn S. Vraniak as Chief Financial Officer
May 2022 " MONTREAL (CANADA) – May 17, 2022 – Inversago Pharma Inc. Mr. Before joining Inversago, Mr. Prior to that, Mr. Additionally, Mr.
- Sosei Heptares and Kallyope Enter Collaboration to Identify and Validate Novel Gastrointestinal GPCR
May 2022 Sosei Heptares and Kallyope Enter Collaboration to Identify and Validate Novel Gastrointestinal Collaboration is part of Sosei Heptares ’ Target Identification and Validation (TIV) strategy to leverage multiple the development of new gastrointestinal therapeutics Tokyo, Japan, Cambridge, UK and New York, USA – May with a goal of creating new drug discovery programs in the area of gastrointestinal diseases. " Read more
- Domain Therapeutics Raises $42m Series A Financing
May 2022 "Published: May 10, 2022 To accelerate clinical development of its best-in-class and first-in-class immuno-oncology programs STRASBOURG, France & MONTREAL- Domain Therapeutics , a biopharmaceutical Read more at the source #DrGPCR #GPCR #IndustryNews
- GPCR Therapeutics Expands Scientific Advisory Board
May 2022 "Seoul, South Korea, 28 April 2022 – GPCR therapeutics , Inc., a venture-backed clinical stage Michel Bouvier , Dr. Luisa Salter-Cid , Dr. Omar Nadeem and Dr. GPCR just had a very successful first meeting including all the Scientific Advisory Board." Read more at the source #DrGPCR #GPCR #IndustryNews
- Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare ...
., March 31, 2022 -- Trevena , Inc. Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines Read more at the source #DrGPCR #GPCR #IndustryNews
- Sosei Heptares Confirms Senior Leadership Changes to Drive the Company Through the Next Stage ...
focused on expanding its GPCR-focused structure-based drug design platform and enhancing translational medicine technology investments, licensing late-stage products for Japan, and strategic acquisitions • Mr Matt Barnes appointed President of Heptares Therapeutics Ltd., and Head of UK R&D Tokyo, Japan and a series of Executive Management changes have been approved at the Company’s 32nd Shareholders’ Meeting Read more at the source #DrGPCR #GPCR #IndustryNews
- Addex Therapeutics Completes Patient Enrollment For Dipraglurant Blepharospasm Phase 2 Clinical ...
Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based blepharospasm, a type of dystonia characterized by involuntary contractions or spasms of the eyelid muscles Dipraglurant selectively targets the metabotropic glutamate receptor subtype 5 (mGlu5) through allosteric modulation to downregulate the neurotransmission believed to cause blepharospasm." Read more at the source #DrGPCR #GPCR #IndustryNews
- Crinetics Pharmaceuticals Announces Pricing Of Underwritten Common Stock Offering
underwriting discounts and commissions and other offering expenses, are expected to be approximately $125.0 million Read more at the source #DrGPCR #GPCR #IndustryNews
- Exscientia welcomes Richard J. Law, as their new Chief Business Officer
March 2022 "Congratulations to Richard J. Law , our newly named Chief Business Officer. Read more at the source #DrGPCR #GPCR #IndustryNews
- Domain Therapeutics and Explicyte enter partnership agreement in immuno-oncology
March 2022 " Explicyte grants Domain Therapeutics exclusivity on data related to GPCR implicated in Strasbourg and Bordeaux, France, March 10, 2022 – Domain Therapeutics , a biopharmaceutical company specializing immuno-oncology (IO), and Explicyte , an expert in the field of IO and innovative target identification through multiparametric Read more at the source #DrGPCR #GPCR #IndustryNews